Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

Detalles Bibliográficos
Autores principales: Regula, Prudhvi, Rosenstreich, David, Jerschow, Elina, Ramesh, Manish, Ferastraoaru, Denisa, Oh, Jessica, Aivazi, Daniella S., Aivazi, Jonathan M., Hudes, Golda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055417/
https://www.ncbi.nlm.nih.gov/pubmed/36164368
http://dx.doi.org/10.1016/j.jacig.2022.04.005
Descripción
Sumario:Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

Ejemplares similares